Evidence map›Paper›PMID 34239704›Full record

ArticleWorld journal of hepatology2021

Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma.

Kazuo Tarao, Akito Nozaki, Hirokazu Komatsu, Tatsuji Komatsu, Masataka Taguri, Katsuaki Tanaka, Testuo Yoshida, Hideki Koyasu, Makoto Chuma, Kazushi Numata and 1 more

Open access · diamondAbstract read
In one paragraph

Article in World journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Comparison of abbreviated MRI and ultrasonography in the detection of early hepatocellular carcinoma: a meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. ASAP ScoreFrontiers in oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Kazuo TaraoTarao's Gastroenterological Clinic, Yokohama 241-0821, Japan. nrg18449@nifty.com.
Akito NozakiGastroenterological Center, Yokohama City University Medical Center, Yokohama 232-0024, Japan.
Hirokazu KomatsuDepartment of Gastroenterology, Yokohama Municipal Citizen's Hospital, Yokohama 240-0855, Japan.
Tatsuji KomatsuDepartment of Clinical Research, National Hospital Organization, Yokohama Medical Center, Yokohama 245-8575, Japan.
Masataka TaguriDepartment of Data Science, Yokohama City University, Yokohama 236-0004, Japan.
Katsuaki TanakaDepartment of Gastroenterology, Hadano Red Cross Hospital, Hadano City 257-0017, Japan.
Testuo YoshidaDepartment of Radiology, Ashigarakami Hospital, Yokohama 258-0003, Japan.
Hideki KoyasuDepartment of Radiology, Koyasu Clinic, Yokohama 241-0821, Japan.
Makoto ChumaGastroenterological Center, Yokohama City University Medical Center, Yokohama 232-0024, Japan.
Kazushi NumataGastroenterological Center, Yokohama City University Medical Center, Yokohama 232-0024, Japan.
Shin MaedaDepartment of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
Yokohama City University · JPYokohama City University Medical Center · JPNational Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn hepatocellular carcinoma (HCC), detection and treatment prior to growth beyond 2 cm are important as a larger tumor size is more frequently associated with microvascular invasion and/or satellites. In the surveillance of very small HCC nodules (≤ 2 cm in maximum diameter, Barcelona clinical stage 0), we demonstrated that the tumor markers alpha-fetoprotein and PIVKA-Ⅱ are not so useful. Therefore, we must survey with imaging modalities. The superiority of magnetic resonance imaging (MRI) over ultrasound (US) to detect HCC was confirmed in many studies. Although enhanced MRI is now performed to accurately diagnose HCC, in conventional clinical practice for HCC surveillance in liver diseases, unenhanced MRI is widely performed throughout the world. While, MRI has made marked improvements in recent years.

aimTo make a comparison of unenhanced MRI and US in detecting very small HCC that was examined in the last ten years in patients in whom MRI and US examinations were performed nearly simultaneously.

methodsIn 394 patients with very small HCC nodules, those who underwent MRI and US at nearly the same time (on the same day whenever possible or at least within 14 days of one another) at the first diagnosis of HCC were selected. The detection rate of HCC with unenhanced MRI was investigated and compared with that of unenhanced US.

resultsThe sensitivity of unenhanced MRI for detecting very small HCC was 95.1% (97/102, 95% confidence interval: 90.9-99.3) and that of unenhanced US was 69.6% (71/102, 95% confidence interval: 60.7-78.5). The sensitivity of unenhanced MRI for detecting very small HCC was significantly higher than that of unenhanced US (

conclusionCurrently, unenhanced MRI is a very useful tool for the surveillance of very small HCC in conventional clinical follow-up practice.

Indexed as

Comparison of magnetic resonance imaging and ultrasoundMagnetic resonance imagingSurveillance of very small hepatocellular carcinomaUltrasoundUnenhanced magnetic resonance imaging

Identifiers

PMID34239704
PMCPMC8239491
OpenAlexW3177123686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.